40 related articles for article (PubMed ID: 36493736)
1. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
2. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
3. Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies.
Hashemi S; Sharifi A; Zareei S; Mohamedi G; Biglar M; Amanlou M
Res Pharm Sci; 2020 Jun; 15(3):226-240. PubMed ID: 33088323
[TBL] [Abstract][Full Text] [Related]
4. Synergy and anti-cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS-RGL1.
Hacisuleyman A; Erman B
Proteins; 2024 May; 92(5):665-678. PubMed ID: 38153169
[TBL] [Abstract][Full Text] [Related]
5. Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interaction.
Ikram S; Sayyah E; Durdağı S
Chembiochem; 2024 Apr; ():e202400008. PubMed ID: 38622060
[TBL] [Abstract][Full Text] [Related]
6. The Missing Link between (Un)druggable and Degradable KRAS.
De Vita E; Maneiro M; Tate EW
ACS Cent Sci; 2020 Aug; 6(8):1281-1284. PubMed ID: 32875070
[No Abstract] [Full Text] [Related]
7. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant-Novel Insights from Computer-Aided Drug Discovery.
Ramalingam PS; Balakrishnan P; Rajendran S; Jothi A; Ramalingam R; Arumugam S
Curr Issues Mol Biol; 2023 Mar; 45(3):2136-2156. PubMed ID: 36975507
[TBL] [Abstract][Full Text] [Related]
8. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
9. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.
Tayubi IA; Madar IH
Comput Biol Med; 2023 Jan; 152():106377. PubMed ID: 36493736
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
12. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
13. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
14. Association analysis between the interaction of RAS family genes mutations and papillary thyroid carcinoma in the Han Chinese population.
Jin M; Li Z; Sun Y; Zhang M; Chen X; Zhao H; Yu Q
Int J Med Sci; 2021; 18(2):441-447. PubMed ID: 33390813
[TBL] [Abstract][Full Text] [Related]
15. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid.
Myers MB; McKim KL; Parsons BL
Mol Carcinog; 2014 Feb; 53(2):159-67. PubMed ID: 22930660
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
